Category Archives: Sec 3 (d)

“Indian CSO letter to the DPIIT on the proposed amendment to the Patent Rules”

20th May, 2019   New Delhi 16 May 2019 To Shri Ramesh Abhishek Secretary, Department for Promotion of Industry and Internal Trade, Ministry of Commerce & Industry, Room No.157 Udyog Bhawan, New Delhi Telephone : 2306 1815, 2306 1667, 23061598(F) … Continue reading

Posted in Fast track patent examination, Indian Patent Law, Patent examination system, Sec 3 (d) | Leave a comment

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These … Continue reading

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

Five years after the Indian Supreme Court’s novartis verdict

Source: Intellectual Property Watch | May 21, 2018 On 1 April 2013, in a packed room inside India’s Supreme Court, a magnificent building in Indo-British architectural style, two judges delivered a verdict that impacted the national and global conversation about … Continue reading

Posted in Novartis Case, Sec 3 (d) | Leave a comment

Weed out evergreen patents

Source: Live Law | May 27, 2018 A recently published report “Pharmaceutical Patent Grants in India: How our safeguards against evergreening have failed and why the system must be reformed“, by Dr. Feroz Ali, Dr. Sudarsan Rajagopal, Dr. Venkata S. … Continue reading

Posted in Evergreening, Patents, Sec 3 (d) | Leave a comment

Rampant evergreening in Indian pharma industry

Source: live mint | April 27, 2018 Pharmaceutical companies commonly used legal argument, as opposed to demonstrating proof of therapeutic efficacy, to overcome anti-evergreening objections India has been at the forefront of developing an alternative model of patent law which … Continue reading

Posted in Indian Patent Law, Indian Patent Office, Sec 3 (d), Uncategorized | Leave a comment

72% of drug patent grants in India for marginal improvements, says study

Source: Business Today | April 25, 2018 Majority of pharmaceutical drug patents granted by India might have skipped elaborate scrutiny, an analysis of patent grants by a team of researchers and patent lawyers reveals.   The report which studied the prosecution … Continue reading

Posted in Indian Patent Office, Patent, Patent Enforcement, Patents, Sec 3 (d) | Leave a comment

An Access Regime based on Indian Patents Act -Review Of “The Access Regime” by Feroz Ali

Source: Even though the Agreement on the trade-related aspects of intellectual property rights (TRIPS) set the minimum standards of protection and enforcement of intellectual property (IP) rights, it could not harmonise the various national patent laws. Irrespective of the … Continue reading

Posted in Compulsory Licensing, FTA, Patent Opposition, Sec 3 (d), TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment